features: Diagnosis

TKI therapy in CP-CML: toxicity management & approaching a cure

VJHemOnc is pleased to bring you a feature covering the current state of the field in the treatment CP-CML with…

Read More

Highlights in myeloid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…

Read More

Genomic testing and clinical decision making in CLL

Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.

Read More

IMW 2021: myeloma updates with Maria-Victoria Mateos and Irene Ghobrial

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

Read More

MDS diagnosis and prognosis with John Bennett

A session with myelodysplastic syndromes (MDS) expert John Bennett who discusses MDS diagnosis and prognosis.

Read More

FDA clears first in vitro diagnostic MRD assay for CLL

The U.S. Food and Drug Administration (FDA) has approved the first and only assay – clonoSEQ®, to screen and assess…

Read More

Genetic mutation signifies new MDS subtype

Published in Blood, a special report has proposed a new, distinct subtype of myelodysplastic syndromes (MDS) based on the presence…

Read More

PROMISE

The Video Journal of Hematological Oncology (VJHemOnc) is pleased to share the success of the PROMISE study by the Dana-Faber…

Read More

iwNHL 2018
E-learning

VJHemOnc is pleased to bring e-learning webcasts from iwNHL 2018- explore updates in lymphoma!

Read More
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals